Harvard startup, Editas Medicine, moves novel gene editing technology forward (Fierce Biotech)
Excerpted from an article in Fierce Biotech
As a startup, Editas Medicine quickly enjoyed the spotlight as a pioneer in the field of gene editing. Its founding VCs attracted a high-profile biotech CEO--Katrine Bosley--last summer, and now it also has the IP it needs from a group of leading research institutions in the forefront of developing CRISPR-Cas9 and TALENs technology.
Editas has sewn up rights to technology developed by the likes of Dr. J. Keith Joung at Mass General, Duke's Duchenne muscular dystrophy (DMD) expert Charles Gersbach and Editas founders Feng Zhang of the Broad Institute and George Church and David Liu of Harvard University, who have all contributed to a hot new field in drug research.